All In Biotech

Investigational drug · Phase 3

Rituxumab

Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Diffuse Large B-cell Lymphoma, DLBCL - Diffuse Large B Cell Lymphoma.

Phase 3

Last checked: Nov 19, 2026Latest source record: Oct 2, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

2

2 still active

All registered trials

4

Any phase or sponsor naming "Rituxumab"

First trial start

2021

Feb 23, 2021

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "Rituxumab", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Diffuse Large B-cell Lymphoma
  • DLBCL - Diffuse Large B Cell Lymphoma

Approved drugs for the same conditions: Lymphoma (non-Hodgkin) · Hematology and blood cancers

Largest trials

Live from ClinicalTrials.gov: studies naming "Rituxumab" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 7 on PubMed

Also in development for Diffuse Large B-cell Lymphoma

  • SintilimabIBI308Phase 321 trials

    Innovent Biologics (Suzhou) Co. Ltd. · Hepatocellular Carcinoma, Solid Tumor, HCC - Hepatocellular Carcinoma

  • MK-2140Zilovertamab Vedotin, VLS-101Phase 39 trials

    Merck & Co. · Diffuse Large B-Cell Lymphoma, Lymphoma, Large B-Cell, Diffuse, B-cell Acute Lymphoblastic Leukemia

  • BirelentinibDZD8586Phase 37 trials

    Dizal Pharmaceuticals · Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Diffuse Large B-Cell Lymphoma, Immune Thrombocytopenia (ITP)

  • MK-1045CN-201Phase 36 trials

    Merck & Co. · Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin, Lymphoma, Follicular

  • BL-M08D1Phase 26 trials

    Sichuan Baili Pharmaceutical Co., Ltd. · Solid Tumors, Gastrointestinal Tumors, Diffuse Large B-Cell Lymphoma

  • GNC-038Phase 24 trials

    Sichuan Baili Pharmaceutical Co., Ltd. · Non-hodgkin's Lymphoma, Primary Central Nervous System Lymphoma, Secondary Central Nervous System Lymphoma

  • and oxaliplatinPhase 22 trials

    Suzhou Suncadia Biopharmaceuticals Co., Ltd. · HER2 Expression Gastric Cancer/Gastroesophageal Junction Adenocarcinoma, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma

  • and prednisonePhase 22 trials

    Genmab · Follicular Lymphoma, Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Roche (Genentech).

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.